Peter Attia· MD
where we're learning geometrically is around inflammation and potentially with these two clinical trials that were published this year or one that was published this year one that was halted likely the methotrexate study was halted early likely because of a positive effect and that won't be announced until the fall but that's to really in interesting proof of concepts of the anti il-1 study and then the methotrexate study we're making no change in lipoproteins you're improving cardiovascular outcomes in my line the next frontier and cardiovascular is what can we do to strengthen the endothelial resilience but cancer man like we're no better at curing cancer - and we were 40 years ago with five exceptions